HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target

Core Insights - GSK plc is recognized as one of the 15 Global Dividend Stocks, indicating its potential for portfolio diversification [1] - HSBC has raised its price target for GSK to 1,500 GBp from 1,200 GBp, maintaining a Reduce rating, reflecting a positive outlook for the pharmaceutical sector in 2026 [2] - GSK is preparing for a leadership transition with Luke Miels set to become CEO, amidst challenges such as US tariffs and the need to replenish its pipeline due to expiring patents [3] Regulatory Updates - The FDA approved GSK's Exdensur as an add-on treatment for severe eosinophilic asthma, marking it as the first biologic with a twice-yearly dosing schedule [4] - In the UK, Exdensur has been approved for use in patients aged 12 and older for asthma and for chronic rhinosinusitis with nasal polyps, showcasing a broader label than the FDA's approval [5] Market Position - GSK operates as a global biopharmaceutical company with a focus on developing medicines and vaccines, particularly in respiratory disease, immunology, and infectious diseases [5]